AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04386902 — intervention group
Intervention type: DEVICE
Intervention: Neurosteer Aurora system
Description: The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface.
Study NCT00659087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Block
Description: Those receiving femoral block postoperatively
Study NCT00659087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Those receiving only usual pain management postoperatively
Study NCT01639352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOM230
Description: Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
Study NCT04517292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin,cisplatin
Description: Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
Study NCT04517292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine,cisplatin
Description: Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
Study NCT02200146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
Study NCT02200146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Prednisone
Description: Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
Study NCT04142333 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: GIA
Description: Patients receive a secure GIA link from their provider and then are able to send their relatives the link to GIA through texting, email, and/or Facebook messenger. Once a relative clicks on the provided link, GIA's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. This can be done either on a smartphone or computer. GIA provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. At the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. The objective of the current study is to evaluate the application of GIA for cascade testing in newly identified high risk breast and gynecologic mutation carriers.
Study NCT03154086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3352589
Description: It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
Study NCT03154086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: It will be available across all strengths to match active drug in the form of tablet for oral administration.
Study NCT03154086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: It will be available across all strengths to match active drug in the form of tablet for oral administration.
Study NCT03135314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cocoa flavanol
Description: 7 days intake of cocoa flavanol supplement (naturex)
Study NCT03135314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7 days of placebo intake
Study NCT02059837 — intervention group
Intervention type: PROCEDURE
Intervention: recurrent pterygium excision and following grafting
Description: The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
Study NCT01219582 — intervention group
Intervention type: DRUG
Intervention: Glucobay M (Acarbose/Metformin, BAY81-9783)
Description: Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
Study NCT03520452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green coffee extract
Description: Reconstituted in water and given to subjects
Study NCT03520452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04232839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416 Reference Formulation
Description: R1 - 60 milligram (6 x 10 milligram tablets) BI 894416 Reference Formulation, immediate release (IR) tablets taken orally with 240 mL of water after an overnight fast of at least 10 hours.
Study NCT04232839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416 Formulation A2
Description: T1 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
Study NCT04232839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416 Formulation C2
Description: T2 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T5 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast.
Study NCT04232839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416 Formulation D2
Description: T3 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation D2, extended release (ER) capsule (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
Study NCT04232839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416 Formulation F2
Description: T4 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T6 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast.
Study NCT02006251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time Instrumentation
Description: To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.
Study NCT02006251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Total Hip Arthroplasty
Description: Total hip arthroplasty performed according to standard of care
Study NCT02006251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Hip Arthroplasty
Description: Total hip arthroplasty performed according to standard of care
Study NCT02361268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialysis-yoga
Description: The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
Study NCT02361268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
Study NCT05715385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser photocoagulation
Description: Laser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion.~Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula.~Duration of about 0.05-0.1 sec is used Number of spots- 100-500
Study NCT05715385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eye drop bromfenac 0.09%
Description: twice daily e/d bromfenac 0.09% for 6 weeks
Study NCT05715385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
Study NCT03307005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate
Description: Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
Study NCT03307005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule one per night taken for 7 nights
Study NCT01298687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.00013%
Description: Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
Study NCT01298687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.00033%
Description: Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
Study NCT01298687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.001%
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Study NCT01298687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.00267%
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Study NCT01298687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost Ophthalmic Solution, 0.004%
Study NCT01298687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost Vehicle
Description: Inactive ingredients used as an active comparator
Study NCT04488770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
Study NCT04488770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching strength placebo capsules will be provided
Study NCT04210986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
Study NCT04210986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
Study NCT02936973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real catgut implantation at acupoints
Description: 1. Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~2. lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week .
Study NCT02936973 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham catgut implantation at acupoints
Description: Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group.
Study NCT04112576 — intervention group
Intervention type: DEVICE
Intervention: Wearable cardiac monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
Study NCT02781090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSFW+
Description: PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
Study NCT02781090 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AHA
Description: The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
Study NCT02781090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine polacrilex
Description: All participants, in both study arms, will be offered a 3-month supply of nicotine patches
Study NCT02781090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: All participants, in both study arms, will be offered a 3-month supply of nicotine patches
Study NCT00198276 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MedPulser Electroporation with bleomycin
Description: The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
Study NCT01766115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: HCV Protease Inhibitor
Study NCT03556904 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablative Radiation Therapy
Description: Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.
Study NCT03556904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone therapy or chemotherapy
Description: Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
Study NCT03556904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone therapy or chemotherapy
Description: Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
Study NCT02074189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Cisplatin
Description: Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
Study NCT02770612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prescribed opioids
Description: Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
Study NCT02562170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TiLoop Bra
Study NCT02562170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protexa
Study NCT01653977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR \< 90/min, CVP >8-12\< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
Study NCT01653977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMIZED
Description: In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
Study NCT02885558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efonidipine
Description: 8 weeks treatment with either efonidipine
Study NCT02885558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: 8 weeks treatment with either nifedipine
Study NCT02636725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
Study NCT02636725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
Study NCT04042025 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Onasemnogene Abeparvovec-xioi
Description: Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Study NCT00392925 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pramlintide acetate 360 mcg
Description: subcutaneous injection, twice a day, 360mcg
Study NCT00392925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate 360 mcg
Description: subcutaneous injection, twice a day, 360mcg
Study NCT00392925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day, 5mg
Study NCT00392925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-pramlintide 600 uL
Description: twice a day
Study NCT00392925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-metreleptin 1 mL
Description: twice a day
Study NCT00392925 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pramlintide acetate 180 mcg
Description: subcutaneous injection twice a day, 180 mcg
Study NCT01952067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: line-to-line reaming and cementing technique
Study NCT01952067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard over-reaming with 2 broach sizes
Study NCT03556956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Tyrosine kinase inhibitor
Study NCT00883064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
Study NCT00883064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
Study NCT00355303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
Study NCT00355303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE2 gel
Description: PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses